Last week, the drugs regulatory body and tabloid scapegoat NICE decided not to allow funding for the bowel cancer drug Avastin on the grounds that spending £21,000 per patient to extend their life by, on average, six weeks was not an effective use of NHS funds (Ben Goldacre has a brilliant column on the media scrum surrounding this decision). It’s a difficult choice, and it must be devastating news for families of bowel cancer sufferers, but on b … Read More
via Atomic Spin





Recent Comments